Time-Limited Therapy with Belatacept in Kidney Transplant Recipients.

Thibault Letellier Delphine KervellaAbderrahmane SadekChristophe MassetClaire GarandeauCynthia FourgeuxVictor GourainJeremie PoschmannGilles BlanchoSimon Villenull On Behalf Of The Divat Consortium

Published in: Journal of clinical medicine (2022)

These findings underpin the use of belatacept as part of a time-limited therapy, in selected kidney transplant recipients, possibly as an approach to allow efficient vaccination against SARS-CoV-2.

Keyphrases

sars cov
mesenchymal stem cells
cell therapy
coronavirus disease
replacement therapy